Literature DB >> 8794902

N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors.

K Liliom1, R Bittman, B Swords, G Tigyi.   

Abstract

Lysophosphatidic acid is the best characterized member of a lipid mediator family with growth factor-like activities that act through a class of G protein-coupled plasma membrane receptors. In Xenopus laevis oocytes, lysophosphatidate activates at least two pharmacologically distinct receptor subtypes distinguished by 1-acyl-sn-glycero-2,3-cyclic phosphate. Both of these naturally occurring ligands elicit oscillatory Cl- currents in the oocyte through G protein-coupled activation of the phosphoinositide/Ca2+ second messenger system, which in turn leads to the opening of Ca(2+)-activated Cl- channels. We developed an improved chemical synthesis and purification procedure for two N-acylated amino acid phosphates. N-Palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids inhibited the lysophosphatidate-activated Cl- currents with IC50 values of 5.4 +/- 0.7 and 6.5 +/- 1.5 nM at the high affinity site and 805 +/- 97 and 172 +/- 36 nM at the low affinity receptor site, respectively. In selective activation of the cyclic lysophosphatidate receptor, IC50 values of 330 +/- 30 and 490 +/- 40 nM were obtained, respectively. The D- and L-stereoisomers were equally effective when applied extracellularly. In contrast, they were ineffective when microinjected into the oocyte, indicating an extracellular site of inhibition. The inhibitors did not alter currents elicited by the different acetylcholine, serotonin, and glutamate receptors expressed heterologously in the oocyte. Pharmacological analysis of the results indicates that N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are potent and specific competitive inhibitors of the lysophosphatidate receptors in the X. laevis oocyte.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794902

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

Review 1.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

2.  Molecular cloning of a high-affinity receptor for the growth factor-like lipid mediator lysophosphatidic acid from Xenopus oocytes.

Authors:  Z Guo; K Liliom; D J Fischer; I C Bathurst; L D Tomei; M C Kiefer; G Tigyi
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

3.  Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions.

Authors:  W Siess; K J Zangl; M Essler; M Bauer; R Brandl; C Corrinth; R Bittman; G Tigyi; M Aepfelbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

4.  Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.

Authors:  Akira Tokumura; Junya Sinomiya; Seishi Kishimoto; Tamotsu Tanaka; Kentaro Kogure; Takayuki Sugiura; Kiyoshi Satouchi; Keizo Waku; Kenji Fukuzawa
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

5.  Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils.

Authors:  N Leitinger; T R Tyner; L Oslund; C Rizza; G Subbanagounder; H Lee; P T Shih; N Mackman; G Tigyi; M C Territo; J A Berliner; D K Vora
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

6.  Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin.

Authors:  A L Khandoga; Y Fujiwara; P Goyal; D Pandey; R Tsukahara; A Bolen; H Guo; N Wilke; J Liu; W J Valentine; G G Durgam; D D Miller; G Jiang; G D Prestwich; G Tigyi; W Siess
Journal:  Platelets       Date:  2008-09       Impact factor: 3.862

7.  Lysophospholipid signaling: beyond the EDGs.

Authors:  William J Valentine; Yuko Fujiwara; Ryoko Tsukahara; Gabor Tigyi
Journal:  Biochim Biophys Acta       Date:  2007-08-25

8.  A lysophosphatidic acid analogue is revealed as a potent inhibitor of phosphatidylcholine synthesis, inducing apoptosis.

Authors:  Geneviéve Gueguen; Virginie Granci; Pierre Rogalle; Fabienne Briand-Mésange; Michéle Wilson; Alain Klaébé; François Tercé; Hugues Chap; Jean-Pierre Salles; Marie-Françoise Simon; Frédérique Gaits
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

Review 9.  LPA receptor signaling: pharmacology, physiology, and pathophysiology.

Authors:  Yun C Yung; Nicole C Stoddard; Jerold Chun
Journal:  J Lipid Res       Date:  2014-03-18       Impact factor: 5.922

10.  Annexin A1 Regulates NLRP3 Inflammasome Activation and Modifies Lipid Release Profile in Isolated Peritoneal Macrophages.

Authors:  José Marcos Sanches; Laura Migliari Branco; Gustavo Henrique Bueno Duarte; Sonia Maria Oliani; Karina Ramalho Bortoluci; Vanessa Moreira; Cristiane Damas Gil
Journal:  Cells       Date:  2020-04-09       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.